Diabetes Research and Clinical Practice
Volume 90, Issue 3 , Pages e54-e56 , December 2010

Diabetic kidney disease: Act now or pay later

  • Robert C. Atkins

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +61 3 9903 0178.
    • ,
  • Paul Zimmet
    • ,
  • For the 2010 World Kidney Day Steering Committee (International Society of Nephrology and International Federation of Kidney Foundations) and the International Diabetes Federation (PZ)

      Affiliations

    • ISN/IFKF 2010 World Kidney Day Steering Committee: William G Couser, MD, Miguel Riella MD, Co-chairpersons. Georgi Abraham MD, Paul Beerkens, John Feehally MD, Guillermo Garcia-Garcia MD, Dan Larson, Philip KT Li MD, Bernardo Rodriguez-Iturbe, MD.

Received 24 November 2009

References 

  1. International Diabetes Federation and International Society of Nephrology . Diabetes and Kidney Disease: Time to Act. Brussels: International Diabetes Federation and International Society of Nephrology; 2003;
  2. Zimmet P, Alberti K, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782–787
  3. King H, Aubert R, Herman W. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21:1414–1431
  4. Yoon K, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006;368:1681–1688
  5. Sicree R, Shaw J, Zimmet P. Diabetes and impaired glucose tolerance. In:  Gan D editors. Diabetes Atlas. 3rd ed.. Brussels: International Diabetes Federation; 2006;p. 15–109
  6. Reutens AT, Prentice L, Atkins R. The epidemiology of diabetic kidney disease. In:  Ekoé J, et al. editor. The epidemiology of diabetes mellitus. 2nd ed.. Chichester: John Wiley & Sons Ltd.; 2008;p. 499–518
  7. International comparisons. In: United States Renal Data System. 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bathesda, Maryland, USA, 2007, pp. 239–254.
  8. S. McDonald, L. Excell, B. Livingston (Eds.) Appendix II, in ANZDATA Registry Report 2008, Australia and New Zealand Dialysis and Transplant Registry, Adelaide, 2008, pp. 1–97.
  9. Yamagata K, et al. Chronic kidney disease perspectives in Japan and the importance of urinalysis screening. Clin. Exp. Nephrol. 2008;12:1–8
  10. Lysaght M. Maintenance dialysis population dynamics: current trends and long term implications. J. Am. Soc. Nephrol. 2002;13:S37–S40
  11. Adler A, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63:225–232
  12. Retnakaran R, et al. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes. 2006;55(6):1832–1839
  13. Parving H, et al. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int. 2006;69(11):2057–2063
  14. Ninomiya T, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J. Am. Soc. Nephrol. 2009;20(8):1813–1821
  15. Dunstan D, et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care. 2002;25(5):829–834
  16. White S, et al. Limited knowledge of kidney disease in a survey of AusDiab study participants. Med. J. Aust. 2008;188(4):204–208
  17. Whaley-Connell A, et al. Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am. J. Kidney Dis. 2009;53(4 Suppl. 4):S11–S21
  18. Thomas M, Viberti G, Groop P. Screening for chronic kidney disease in patients with diabetes: are we missing the point?. Nat. Clin. Pract. Nephrol. 2008;4(1):2–3
  19. Holman R, et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 2008;359(15):1577–1589
  20. Bilous R. Microvascular disease: what does the UKPDS tell us about diabetic nephropathy?. Diabetes Med. 2008;25(Suppl. 2):25–29
  21. Gaede P, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N. Engl. J. Med. 2008;358(6):580–591
  22. Patel A, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829–840
  23. Group AC, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–2572
  24. Zoungas S, et al. The combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes; new results from ADVANCE. Diabetes Care. 2009;(August):(Epub ahead of print)
  25. Ruggenenti P, et al. Preventing microalbuminuria in type 2 diabetes. N. Engl. J. Med. 2004;351(19):1941–1951
  26. Parving H, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 2001;345(12):870–878
  27. Lewis E, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 2001;345:851–860
  28. Burney B, Kalaitzidis R, Bakris G. Novel therapies of diabetic nephropathy. Curr. Opin. Nephrol. Hypertens. 2009;18(2):107–111

PII: S0168-8227(09)00493-8

doi: 10.1016/j.diabres.2009.11.022

Diabetes Research and Clinical Practice
Volume 90, Issue 3 , Pages e54-e56 , December 2010

Article Tools